The share price of listed cancer diagnostics company Pacific Edge has dropped by about 25% in NZX trading today after it confirmed it had lost reimbursement on about 60% of its US revenue.
The loss of the public Medicare funding for its Cxbladder tests paid out under a local coverage determination
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
